Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

2.9K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.9K
International Nursing Organizations II01:28

International Nursing Organizations II

1.1K
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
1.1K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

23
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
23
Guidelines For Measuring Vital Signs01:19

Guidelines For Measuring Vital Signs

1.8K
Following these guidelines can help nurses accurately measure vital signs, assess changes in patient conditions, and provide timely treatment when necessary. Adhering closely to the guidelines ensures the accuracy and reliability of the results.
Before taking a patient's vital signs, a nurse would consider and assess the patient's comfort level and ensure appropriate equipment is available.
1.8K
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

613
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
613
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

25
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

Rethinking Myocarditis and Genetic Susceptibility in Severe Paediatric Cardiomyopathy.

European journal of heart failure·2026
Same author

A qualitative study of goals of hospital care and health outcome goals among patients admitted for heart failure.

Patient education and counseling·2026
Same author

Interaction between GRASP-HF and ICARe-HF: a strategic alliance to improve heart failure care in Europe and beyond.

European heart journal. Quality of care & clinical outcomes·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026

Related Experiment Video

Updated: Aug 16, 2025

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

6.0K

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines.

Daniela Tomasoni1, Marianna Adamo1, Biykem Bozkurt2

  • 1Cardiology and Cardiac Catheterization Laboratory, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|December 22, 2022
PubMed
Summary

Recent guidelines for heart failure with reduced ejection fraction (HFrEF) emphasize four key drug classes. Early initiation of these treatments is crucial for improving cardiovascular outcomes and reducing hospitalizations.

Keywords:
ACC/AHA/HFSAComparisonESCGuidelinesHFrEFHeart failure

More Related Videos

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

17.7K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

17.7K

Related Experiment Videos

Last Updated: Aug 16, 2025

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

6.0K
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

17.7K
Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

17.7K

Area of Science:

  • Cardiology
  • Clinical Practice Guidelines

Background:

  • Large randomized controlled trials (RCTs) have significantly advanced heart failure with reduced left ventricular ejection fraction (HFrEF) treatment.
  • Recent European Society of Cardiology (ESC) and ACC/AHA/HFSA guidelines (2021/2022) incorporate these advances.

Purpose of the Study:

  • Compare the 2021 ESC and 2022 ACC/AHA/HFSA guidelines for HFrEF.
  • Highlight consistent recommendations and identify minor differences between the guidelines.

Main Methods:

  • Comparative analysis of the European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) guidelines.
  • Review of evidence supporting drug classes for HFrEF treatment.

Main Results:

  • Both guidelines recommend four foundational drug classes for HFrEF: angiotensin-converting enzyme inhibitors/angiotensin receptor neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter 2 inhibitors.
  • Emphasis is placed on early administration of all four drug classes, rather than specific sequences.
  • Additional therapies like ivabradine, hydralazine nitrates, digoxin, and vericiguat are considered for select patients.

Conclusions:

  • The ESC and ACC/AHA/HFSA guidelines demonstrate substantial alignment in HFrEF management.
  • The guidelines reflect a growing body of evidence for novel HFrEF treatments and comorbidities.